Cargando…
MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide
BACKGROUND: Monoclonal antibodies (mAbs) which potently neutralize a broad range of HIV isolates are potential microbicide candidates. To date, topical application of mAbs in humans and their stability in vaginal secretions has not been studied. OBJECTIVES: To assess the pharmacokinetics and safety...
Autores principales: | Morris, Georgina C., Wiggins, Rebecca C., Woodhall, Sarah C., Bland, J. Martin, Taylor, Carol R., Jespers, Vicky, Vcelar, Brigitta A., Lacey, Charles J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278856/ https://www.ncbi.nlm.nih.gov/pubmed/25546420 http://dx.doi.org/10.1371/journal.pone.0116153 |
Ejemplares similares
-
Safety of G2-S16 Polyanionic Carbosilane Dendrimer as Possible HIV-1 Vaginal Microbicide
por: Martin-Moreno, Alba, et al.
Publicado: (2022) -
Vaginal rings for delivery of HIV microbicides
por: Malcolm, R Karl, et al.
Publicado: (2012) -
The Development of Vaginal Microbicides for the Prevention of HIV Transmission
por: Weber, Jonathan, et al.
Publicado: (2005) -
Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015) -
G2-S16 dendrimer microbicide does not interfere with the vaginal immune system
por: Martín-Moreno, Alba, et al.
Publicado: (2019)